Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate
Find out how Takeda’s pediatric Entyvio review could change biologic treatment choices in ulcerative colitis and Crohn’s disease.
Accro Bioscience’s $50m round signals growing interest in targeted IBD immunology
IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.
Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?
Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.
Early-stage biosimilar deal between Samsung Bioepis and Sandoz covers vedolizumab and four undisclosed molecules
Samsung Bioepis and Sandoz expand their biosimilar partnership to cover vedolizumab SB36 and four early-stage candidates. What this means for the IBD biologics market.
AbbVie’s AFFIRM trial: what clinicians should watch next for risankizumab in Crohn’s disease
AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
NIM-1324 enters Phase 2 as NImmune Biopharma tests immunometabolism as the next frontier in inflammatory bowel disease
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.
Nimbus Therapeutics tests a dual inflammation and repair thesis with SIK2 inhibitors
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.
Can subcutaneous infliximab change how clinicians manage drug holidays in Crohn’s disease and ulcerative colitis
New ECCO 2026 data explore whether subcutaneous infliximab can reliably recapture disease control after treatment interruption. Read the analysis.
Sinorda bets on bispecifics with WuXi Biologics for IBD and autoimmune expansion
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and clinical manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune conditions. The agreement will see Sinorda Biomedicine utilize WuXi Biologics’ CRDMO capabilities to support preclinical development, IND-enabling activities, and global clinical supply for SND006, […]